#

Depression (ALTO)

  • Compensation to be determined
  • 13 visits (enrollment open)
#

Between 18 - 65 Years

#
Male or Female
#
Smoker & Non-Smoker

Description

The purpose of this research study is to understand how ALTO-100 or placebo affects the symptoms of depression as well as the brain patterns, thinking (cognition), and behavior that can be seen in a participant with MDD prior to and when receiving the study intervention, either ALTO-100 or placebo. Because of the experimental nature of the study data, we will not provide you with your individual research results. 

There are two different conditions for your antidepressant history to be eligible. Either (1) you are currently on an antidepressant at an acceptable dose for at least 6 weeks and have not gotten at least 50% better; or (2) you are not currently on any antidepressant. If you are currently taking one antidepressant at an acceptable dose at Visit 2, you will continue using that medication and should stay at the same dose for the double-blind period of study. You will be asked about all of your depression treatments in the past 26 months. 

If you are taking more than one antidepressant, you can still potentially enter the study only if you reduce your multiple antidepressants to a single medication before Visit 2. But you should only reduce or change your antidepressant medications with the approval and guidance of your prescribing doctor.

Is this not what you are looking for?
Check out our other studies.

Related Studies

#

Gout

  • Compensation to be determined
  • Clinical visits 17
#
Between 19+ Years

#
Male or Female
#
Smoker & Non-Smoker
#

Small Cell Lung Cancer

  • Compensation to be determined
  • Clinical visits 24
#
18+ Years

#
Male or Female
#
Smoker & Non-Smoker
#

Chronic Idiopathic Urticaria

  • Compensation to be determined
  • 13 clinic visits including 3 safety follow-up visits
#
Between 18 - 75 Years

#
Male or Female
#
Smoker & Non-Smoker
© 2024 Access Research Institute. All Rights Reserved